Overview

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a phase IV study of indacaterol 75 μg single-dose compared to placebo in moderate-severe COPD patients with breathing symptoms to assess time to patient's perception of onset of effect.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals